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Abstract
Taxanes are potent inhibitors of cell motility, a property implicated in their antiangiogenic and antimetastatic activity
and unrelated to their antiproliferative effect. The molecular mechanism of this anti-motility activity is poorly under-
stood. In this study, we found that paclitaxel induced tubulin acetylation in endothelial and tumor cells, at concentra-
tions that affected cell motility but not proliferation (10−8 to 10−9 M, for 4 hours). Induction of tubulin acetylation
correlated with inhibition of motility but not proliferation based on a comparison of highly and poorly cytotoxic taxanes
(paclitaxel and IDN5390) and tumor cell lines sensitive and resistant to paclitaxel (1A9 and 1A9 PTX22). Consistent
with the hypothesis that tubulin deacetylase activity might affect cell response to the anti-motility activity of taxanes,
we found that overexpression of the tubulin deacetylase SIRT2 increased cell motility and reduced cell response to
the anti-motility activity of paclitaxel. Conversely, the SIRT2 inhibitor splitomicin reduced cell motility and potentiated
the anti-motility activity of paclitaxel. The inhibitory effect was further potentiated by the addition of the HDAC6
inhibitor trichostatin A. Paclitaxel and splitomicin promoted translocation into the nucleus—and hence activation—
of FOXO3a, a negative regulator of cell motility. This study indicates a role for SIRT2 in the regulation of cell motility
and suggests that therapies combining sirtuin inhibitors and taxanes could be used to treat cell motility–based patho-
logic processes such as tumor angiogenesis, invasion, and metastasis.
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Introduction
Cell motility is a central event in a number of physiological and path-
ologic processes. Agents that perturb the finely tuned microtubule
organization, stability, and dynamics inhibit cell motility and have
been proposed as therapeutic inhibitors of motility-based pathologies,
including cancer metastasis and pathologic angiogenesis. Among these,
the antineoplastic drug paclitaxel and other taxanes have anti-motility
activity for tumor and endothelial cells, a property thought to con-
tribute to their antimetastatic and antiangiogenic activity. This effect
of tubulin-targeting compounds has opened new therapeutic oppor-
tunities to target the tumor vascular compartment and the metastatic
dissemination of tumor cells [1,2].
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The molecular mechanisms of the anti-motility activity of taxanes
is still poorly understood [3]. Three lines of evidence indicate that
the effect of taxanes on cell motility is distinct from their cytotoxic
activity. First, cell motility is inhibited by taxanes at concentrations
lower than the cytotoxic concentrations. A short exposure to low
concentrations of paclitaxel has no effect on cell proliferation or
apoptosis but affects microtubule dynamics, cell motility, and morpho-
genesis [4–7]. Second, tumor cells harboring the A364T mutation
in β-tubulin are resistant to the antiproliferative activity of paclitaxel
but nonetheless remain sensitive to the anti-motility effect of taxanes
[8]. Third, the seco-derivative taxane IDN5390 exhibits potent anti-
motility and antiangiogenic activity but a lower cytotoxicity com-
pared to paclitaxel [9,10], further supporting the concept that the
antiproliferative and anti-motility activity of taxanes work through
different pathways.
Microtubule-dependent events potentially responsible for the in-
hibition of cell motility—rather than proliferation—include pro-
motion of microtubule stability, alteration of microtubule dynamics,
and induction of tubulin posttranslational modifications such as
acetylation. Taxanes increase tubulin acetylation [11,12], although
the functional relevance of this event in inhibition of cell motility has
not been clarified.
Reversible posttranslational modifications of tubulin are considered
responsible for the structural and functional diversity of microtubule
subpopulations, characterized by a fine spatial and temporal regulation
[12,13]. Acetylation occurs at the ɛ-amino group of Lys40 in the
α-tubulin, and although other acetylation sites have been recently
identified [14], acetylation of this particular lysine has been correlated
with changes in cell motility [12]. Tubulin acetylation is mainly regu-
lated by a complex constituted by the class IIb histone deacetylase
HDAC6 and the NAD-dependent histone deacetylase SIRT2.
Sirtuins are NAD+-dependent protein deacetylases and are impli-
cated in a variety of biologic processes including metabolic regulation
and cellular response to a variety of physiological stresses. SIRT2 is pre-
dominantly cytoplasmic but shuttles between the nuclear compart-
ment and the cytoplasm during interphase, and it is mainly nuclear
during mitosis [15]. It deacetylates molecular targets both in the nucleus
and cytoplasm, such as histone H4 [16] and tubulin [17], and is involved
in the regulation of cell cycle progression [18–20].
HDAC6 and SIRT2 interact in the cytoplasm, where they bind
tubulin, colocalize with microtubules, and deacetylate tubulin
[17,21,22]. HDAC6 and SIRT2 differ in their ability to deacetylate
tubulin substrates, because SIRT2 deacetylates tubulin also as cell
lysate–derived heterodimers and taxol-stabilized microtubules whereas
these forms of tubulin are relatively resistant to HDAC6 [17,23].
Acetylation of α-tubulin is a marker of microtubule stability,
although whether there is a causal relationship between acetylation
and stability is still debated [12]. Tubulin acetylation/deacetylation
participates in the regulation of cell motility: Overexpression of
HDAC6 decreases tubulin acetylation and increases cell motility in
fibroblast [21,24] and in breast cancer cells [25]. Conversely, reduced
cell motility and increased tubulin acetylation are observed in fibro-
blasts and transformed cells following reduction of HDAC6 activity,
either by deacetylase inhibitors [such as trichostatin A (TSA) and
tubacin] [24,26] or following knockdown of the deacetylase [26,27].
Less is known on the role of SIRT2 in cell motility.
Taxanes and tubulin deacetylases share the same target, tubulin,
and both induce changes in tubulin acetylation. Both tubulin acetyla-
tion and binding of taxanes are predicted to occur in the lumen of
the microtubule structure [3,11,13], suggesting that these compounds
modulate the transmission of signals from the lumen of the micro-
tubules to the cytoskeleton.
Selective HDAC6 inhibitors synergize with taxanes, and combina-
tion regimens that include both classes of compounds have proven
effective in preclinical studies and are currently in clinical trials in
cancer patients [28,29]. Inhibitors of sirtuins have also been proposed
as antineoplastic agents [23,29], although the exact sirtuin involved
(SIRT1 vs SIRT2), the mechanisms of action, and the possibilities of
combinations with other agents have not been investigated.
This study was designed to investigate whether modification of
tubulin acetylation, particularly through the modulation of SIRT2
activity, might affect cell susceptibility to the anti-motility effect of
taxanes. We describe that modulation of SIRT2 activity affects cell
motility and response to the anti-motility activity of taxanes, suggesting
that specific inhibitors of SIRT2 might represent a new tool to poten-
tiate the activity of taxanes in antineoplastic combination therapies.
Materials and Methods
Reagents
Paclitaxel and IDN5390 were provided by Indena S.p.A. (Milan,
Italy). Splitomicin [30], TSA, and sirtinol (Sigma, St Louis, MO) were
dissolved in DMSO (1000× stock solution) and further diluted in test
medium immediately before the assay (control cells received the same
amount of DMSO). Nicotinamide (Sigma) was dissolved in water.
Cells
Primary cultures of endothelial cells (human umbilical vein endothelial
cells [HUVECs]) were isolated from umbilical cord veins and grown on
1% gelatin-coated flasks in M199 supplemented with 10% FBS, 10%
newborn calf serum, 20mMHepes, 2 mM glutamine, 6 U/ml heparin,
50 μg/ml endothelial cell growth factor, penicillin, and streptomycin.
Cells were used between the third and fifth passages. The 1A9 human
ovarian carcinoma cell line and its paclitaxel-resistant variant, 1A9 PTX22
[31], were obtained from A. Fojo (National Cancer Institute, National
Institutes of Health, Bethesda, MD) and grown in RPMI with 10%
FBS and 2 mM glutamine. Stocks of cell lines, authenticated by short-
tandem repeat profiling (AmpFlSTR Identifiler Plus PCR Amplifica-
tion Kit; Applied Biosystems, Carlsbad, CA), were stored frozen in
liquid nitrogen and used within 8 weeks after thawing.
Western Blot Analysis of Tubulin Acetylation
Endothelial or tumor cells were plated in a 24-well plate in com-
plete medium. The next day, cells were treated with the indicated
compound for 4 hours. After washing with phosphate-buffered saline
(PBS), cells were lysed in 100 μl of lysis buffer [20 mM Tris-HCl
(pH 7.6), 170 mM NaCl, 1 mM EDTA, 1 mM DTT, 1% Triton,
5 μM TSA, and Roche Protease Inhibitor Cocktail Tablet] and centri-
fuged at 14000 rpm for 10 minutes. Proteins were electrophoresed on a
10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-
PAGE) gel and transferred to a nitrocellulose membrane (Schleicher
& Schuell, Dassel, Germany). After blocking overnight at 4°C with
ECL advance blocking agent, membranes were probed with anti-
acetylated tubulin antibody (1:2000, T6793 clone 6-11B-1) or anti-
total tubulin antibody (1:500, T9026), both antibodies from Sigma,
in PBS/0.5% Tween, for 1 hour at room temperature, followed by
peroxidase-conjugated anti-mouse IgG (Sigma) and Amersham ECL
Plus Western Blotting Detection Reagent (GE Healthcare Europe
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GmbH, Milan, Italy). After scanning (Duoscan T1200, AGFA), densi-
tometry was analyzed with Gel-Pro Analyzer 3.1 (Media Cybernetics,
Silver Spring, MD).
Immunofluorescence Analysis of Tubulin Acetylation
Endothelial cells were plated on coverslips and incubated overnight.
After treatment with IDN5390 or paclitaxel (10 nM for 4 hours),
cells were fixed with methanol at −20°C for 10 minutes. Coverslips
were washed in PBS and incubated in blocking solution (5% normal
goat serum in PBS) for 30 minutes at room temperature. Incubation
with antibodies against acetylated tubulin (1:1000, T6793, Sigma) in
blocking solution was carried out for 1 hour at room temperature. After
washing, tetramethylrhodamine isothiocyanate (TRITC)-conjugated
rabbit anti-mouse IgG (1:300, Sigma) in blocking solution was
incubated for 1 hour. Nuclei were counterstained by 4′,6-diamidino-
2-phenylindole (DAPI; 100 μg/ml, Sigma). Slides were analyzed by a
fluorescence microscope (OLYMPUS IX70).
Colocalization of SIRT2 with Microtubules
Endothelial cells were plated on coverslips and incubated overnight.
After treatment with paclitaxel or IDN5390 (100 nM for 4 hours), cells
were fixed with methanol at −20°C for 10 minutes. Coverslips were
then washed in PBS and incubated in blocking solution (5% normal
goat serum in PBS) for 30 minutes at room temperature. Slides were
incubated with fluorescein isothiocyanate (FITC)–conjugated mono-
clonal anti–β-tubulin (1:25, Sigma) and chicken anti-human SIRT2
(1:50, [17]), in blocking solution for 1 hour at room temperature, fol-
lowed by incubation with TRITC-conjugated rabbit anti-chicken IgG
(1:50; Jackson ImmunoResearch, Newmarket, United Kingdom).
Slides were analyzed with a Zeiss LSM 510 Meta confocal microscope.
Immunofluorescence Analysis of FOXO3a
HUVECs were plated on coverslips and incubated overnight. After
treatment with paclitaxel (10 nM), splitomicin (1.2 mM), or TSA
(1 μM) for 4 hours, cells were fixed with 3% paraformaldehyde for
20 minutes, washed in PBS, and permeabilized with 0.1% Triton X-100
in PBS. After blocking (in 5% goat serum in PBS) for 30 minutes, cells
were stained with antibodies against FOXO3a (1:50, 75D8; Cell Sig-
naling Technology, Danvers, MA) in blocking solution for 40 min-
utes at 37°C, followed by Alexa Fluor 546 anti-rabbit IgG (1:100;
Invitrogen, Carlsbad, CA) for 45 minutes at room temperature. Nuclei
were counterstained by DAPI (100 μg/ml, Sigma). Slides were analyzed
with a Zeiss LSM 510 Meta confocal microscope.
Motility Assay
Chemotaxis was assessed using Boyden chambers and gelatin-coated
polycarbonate nucleopore filters (8-μm pore size). The supernatant of
NIH-3T3 cells was used as the attractant. Cells were resuspended in
Dulbecco’s modified Eagle’s medium/0.1% BSA at a concentration
of 1.5 × 106/ml and added to the upper compartment of the chamber.
IDN5390, paclitaxel, or histone deacetylase inhibitors at the indicated
concentration were added to the cells and incubated throughout the
assay (4 hours). At the end of incubation, filters were stained with
Diff-Quik (Marz-Dade, Dundingen, Switzerland) and the migrated
cells were counted in 10 high-power fields.
Proliferation Assay
Cells (2–3 × 103 cells/well) were plated in a 96-well plate in complete
medium. After 24 hours, IDN5390, paclitaxel, or histone deacetylase
inhibitors at the indicated concentration were added and incubated for
4 hours. Cells were then washed and incubated in culture medium for
an additional 72 hours. In parallel plates, cells were exposed to the
compounds for the entire duration of the assay (72 hours). Cells were
fixed and stained with 0.5% crystal violet in 20% methanol. The stain
was eluted with a 1:1 solution of ethanol/0.1 M sodium citrate, and
the absorbance at 540 nm was measured.
SIRT2 Stable Transfection
Human wild-type green fluorescent protein (GFP)-SIRT2 and the
catalytically inactive mutant N168A plasmids were prepared as de-
scribed [17]. Subconfluent 1A9 human ovarian carcinoma cells were
transfected using Lipofectin Reagent (Invitrogen) following manufac-
turer’s protocol. For selection, cells were cultured in medium contain-
ing 800 μg/ml of G418 (Invitrogen) and subsequently enriched in
GFP-expressing cells by fluoresence-activated cell sorter (FACS). West-
ern blot analysis of cell lysates with anti-SIRT2 antibody [17] confirmed
that the transfected cells produced similar amounts of wild-type and
mutated proteins that were barely detectable in parental cells.
SIRT2 Silencing
HUVECs were transiently transfected with siRNA for human
SIRT2 (mix of Hs_SIRT2_1_HP and Hs_SIRT2_4_HP) or HDAC6
(Hs_HDAC6_6_HP, all from Qiagen, Hilden, Germany) by electro-
poration. Forty-eight hours later, cells were subjected to a second round
of transfection, and after additional 48 hours, cells were tested for tran-
script expression, tubulin acetylation, and motility. Silencing of the
transcripts was verified by real-time reverse transcription–polymerase
chain reaction (PCR; TaqMan Gene Expression Assay Hs00247263-m1
and Hs00195869-m1; Applied Biosystems), normalizing data on 18s
rRNA expression (Assay Hs99999901-s1; Applied Biosystems).
Results
We have investigated the activity of taxanes on endothelial and tumor
cell motility, which represents critical events in the processes of, respec-
tively, tumor angiogenesis and metastasis. To focus on events associ-
ated with inhibition of cell motility rather than proliferation, we used
experimental conditions in which taxanes inhibited cell motility with-
out affecting proliferation [4,8]. We also used the seco-derivative
taxane IDN5390, which exhibits anti-motility activity and reduced
cytotoxicity compared to paclitaxel ([9,10], summarized in Table W1).
Endothelial cells were exposed to paclitaxel or IDN5390 for 4 hours,
and tubulin acetylation levels were assessed. Both PTX and IDN5390
increased the levels of acetylated tubulin in treated HUVECs, using
either immunofluorescence (Figure 1A) or Western blot analysis (Fig-
ure 1B). Induction of tubulin hyperacetylation paralleled the inhibition
of cell motility but not of proliferation, which occurred at concentra-
tions much higher than those required to inhibit motility (particularly
for IDN5390), even when cells were treated with the taxane for longer
times or cytotoxicity was assessed by quantifying the mitotic index
(Figures 1C and W1).
To confirm the separation between the effect of taxanes on cell
proliferation and motility also in cancer cells, we used 1A9 PTX22 cells,
which are resistant to the antiproliferative activity of taxanes but sen-
sitive to their anti-motility effect, as shown by the previous finding that
paclitaxel and IDN5390 induced a comparable reduction of motility in
paclitaxel-resistant 1A9 PTX22 cells and in the paclitaxel-sensitive
parental 1A9 cells ([8,9], summarized in Table W2). Interestingly,
both the highly cytotoxic paclitaxel and the low cytotoxic IDN5390
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induced tubulin acetylation in 4 hours at concentrations sufficient to
inhibit cell motility (∼30 nM) in both cell lines irrespective of their
sensibility to inhibition of proliferation (Figures 1D and W2).
These findings support the hypothesis that tubulin acetylation might
be implicated in the anti-motility activity of taxanes. To test this pos-
sibility, we first tested whether inhibitors of the tubulin deacetylases
HDAC6 and SIRT2 affected the motility of endothelial cells. As re-
ported, TSA, a broad spectrum hydroxamic acid inhibitor of class I
and II HDAC (which include HDAC6), inhibited endothelial cell
motility, although inhibitors of sirtuins appeared more effective (Fig-
ure 2A). Nicotinamide, sirtinol, and splitomicin inhibited endothelial
cell motility in a dose-dependent manner with IC50 of 47.9 ± 0.7 mM,
43.3 ± 0.3 μM, and 1.6 ± 0.2 mM, respectively (not shown and
Figure 2B). Inhibition of cell motility by splitomicin significantly
correlated with induction of tubulin acetylation (P = .01; Figure 2, B
and C).
Splitomicin was not as potent as TSA in promoting tubulin acetyla-
tion (TSA induced a 26.3 ± 8.4 fold increase of acetylation, not shown),
but it was more potent in inhibiting motility (Figure 2A).
Because splitomicin is not selective for SIRT2 and inhibits all
sirtuins, we further tested the role of SIRT2 using siRNA knockdown
in endothelial cells and SIRT2 stable overexpression in cancer cells.
Silencing of SIRT2 (67% reduction measured by real-time PCR)
was accompanied by decreased motility and increased tubulin acetyla-
tion compared to mock-transfected cells (Figure 2D). Consistent with
the different potency of SIRT inhibitors and TSA in affecting cell
motility and tubulin acetylation, silencing of SIRT2 was more effective
in inhibiting cell motility than silencing of HDAC6 (62% reduction)
although the latter was more effective in increasing tubulin acetyla-
tion (Figure 2D). To investigate the role of SIRT2 overexpression on
cell motility, we stably transfected 1A9 cells to overexpress wild-type
(1A9-S2) or catalytically inactive SIRT2 (1A9-mutS2, Figure W3).
Overexpression of SIRT2 did not relevantly affect cell proliferation
(doubling time was 23.1 ± 3.4 and 21.9 ± 2.3 hours for 1A9-S2 and
1A9-mutS2, respectively), morphology, or tubulin organization (Fig-
ure W4). However, overexpression of SIRT2 markedly increased cell
motility and decreased the levels of tubulin acetylation (Figure 2E ),
further confirming that catalytically active SIRT2 regulates cell motility.
Interestingly, 1A9-mutS2 cells presented a slightly increased tubulin
acetylation and decreased cell motility compared to parental 1A9 cells
(not shown), suggesting that in this system the catalytically inactive
SIRT2 might act as an inhibitor of endogenous SIRT2.
Next, we tested the role of SIRT2 in the anti-motility activity of
taxanes. SIRT2-overexpressing 1A9-S2 cells were less responsive to
the anti-motility activity of both paclitaxel and IDN5390 than control
1A9-mutS2 cells (Figure 3, A and B, and Table 1). Moreover, the dif-
ference in tubulin acetylation between 1A9-S2 and 1A9-mutS2 cells
was maintained after taxane treatment. SIRT2-overexpressing cells
exposed for 4 hours to paclitaxel or IDN5390 showed lower tubulin
acetylation compared to control cells (Figure 3, C and D). Again, the
differential sensitivity in terms of cell motility was dissociated from the
antiproliferative response: The antiproliferative activity of both taxanes
was unaffected by changes in SIRT2 activity in cells treated for either
4 or 72 hours (Table 1).
To investigate whether SIRT2 might be a direct target of taxanes,
we analyzed the effect of paclitaxel on SIRT2 cellular localization and
enzymatic activity. Confocal microscopy analysis confirmed that SIRT2
colocalizes with microtubules (Figures 3E and W5). Treatment of cells
with paclitaxel or IDN5390 did not affect SIRT2 colocalization with
the microtubules. Similar results were observed with HDAC6 (not
shown). In addition, paclitaxel did not affect SIRT2 deacetylase activity
on purified tubulin (Figure W6).
Next, we investigated the possibility that taxanes and SIRT2 in-
hibitors might synergize. We tested the activity of a combination of
splitomicin and paclitaxel on endothelial cell motility. Splitomicin
potentiated the anti-motility activity of paclitaxel (Figure 4A). The
IC50 of paclitaxel was 30.5 ± 6.4 when tested alone and 10.4 ±
4.9 in the presence of splitomicin (1.2 mM). To determine whether
splitomicin and paclitaxel interacted synergistically, additively, or
antagonistically, we calculated the combination index (CI) [32]. The
Figure 1. Effect of paclitaxel and IDN5390 on tubulin acetylation
and motility in endothelial and tumor cells. (A) Immunofluorescence
analysis of acetylated tubulin in HUVECs untreated or treated with
10 nM paclitaxel or IDN5390 for 4 hours (scale bar, 20 μm). (B) West-
ern blot analysis of acetylated and total tubulin in HUVECs exposed
for 4 hours to increasing concentrations of paclitaxel or IDN5390.
(C) Increased tubulin acetylation (black circles), decreased cell motil-
ity (open squares), and unaffected cell proliferation (open diamonds,
dotted line) after a 4-hour exposure to IDN5390. Tubulin acetylation
is expressed as fold increase of untreated cells and was calculated
as the ratio of optical density values of acetylated tubulin versus total
tubulin. Migration and proliferation are expressed as percentage of
control, untreated cells. (D) Western blot analysis of acetylated
and total tubulin comparing the response of sensitive 1A9 and
paclitaxel-resistant 1A9 PTX22 cells to a 4-hour exposure to paclitaxel
or IDN5390.
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combination resulted synergistic (CI < 1) at the highest concentrations
of the two agents but not at lower concentrations, suggesting that the
potentiating effect of splitomicin was maximal at the most effective
concentrations of the compound (Table W3). Under these conditions
(4-hour exposure), the combination of the two drugs did not produce
increased antiproliferative activity (Figure 4A), although a longer expo-
sure (72 hours) to splitomicin inhibited cell proliferation (not shown),
possibly through an inhibitory activity on SIRT1. A similar potentia-
tion of paclitaxel anti-motility activity was also induced by the addition
of 1 μM TSA (IC50 of paclitaxel in the presence of TSA was 13.3 ±
2.7 nM, not shown). We therefore tested whether TSA might fur-
ther potentiate the activity of paclitaxel/splitomicin. The combination
paclitaxel/splitomicin/TSA was even more effective in inhibiting cell
motility (Figure 4B). When exposed for 4 hours to paclitaxel in com-
bination with the two histone deacetylase inhibitors, endothelial cell
motility was almost completely abolished and tubulin acetylation was
highly increased, whereas proliferation was not affected.
Finally, we investigated the effect of paclitaxel and splitomicin on
the transcription factor FOXO3a, a negative regulator of angiogenesis
and cell motility. Because the nuclear localization of FOXO3a is
an indicator of its activity, we investigated whether paclitaxel and
splitomicin affected FOXO3a cellular localization. Immunofluorescence
analysis of untreated HUVECs showed FOXO3a mainly in the cyto-
plasm (Figure 5). After treatment with paclitaxel (for 4 hours, in the same
conditions used in the motility assays), FOXO3a showed a predominant
nuclear localization. Interestingly, splitomicin too induced translocation
of FOXO3a to the nucleus, although some positivity remained in the
cytoplasm. After exposure to a combination of paclitaxel and splitomicin,
endothelial cells presented a higher localization of FOXO3a in the
nucleus, which further increased when TSA was added to the com-
bination (Figure 5).
Altogether these findings indicate that combination of SIRT2 in-
hibitors with taxanes increases their anti-motility activity and point
to FOXO3a as a major mediator of this effect.
Discussion
Inhibitors of motility can impact on the design of therapies for
cell motility–based pathologic processes such as tumor angiogenesis,
Figure 2. Effect of SIRT2 modulation in cell motility. (A) Effect of different histone deacetylase inhibitors on endothelial cell motility. Cells
were exposed to splitomicin (2.4mM), sirtinol (50 μM), nicotinamide (75mM), or TSA (1 μM) for the duration of the assay (4 hours).Motility is
expressed as percentage of control migration in the absence of inhibitors (mean and SE of values from two to four experiments). *P ≤ .01
and **P≤ .001 compared to control (analysis of variance followed by Dunnet test). (B) Concentration-dependent inhibition of motility (open
squares) and tubulin acetylation (black circles) by splitomicin. For motility, data are the percentage of control motility (mean and SE of values
from six experiments). Tubulin acetylation, evaluated by Western blot, is expressed as fold increase of untreated cells, calculated as in
Figure 1 (mean of four experiments). (C) Effect of splitomicin on tubulin acetylation: Western blot analysis of acetylated and total tubulin
in HUVECs exposed for 4 hours to splitomicin. (D) Migration (expressed as percentage of control) and tubulin acetylation of endothelial cells
transiently transfected with SIRT2 or HDAC6 siRNA. Results are from one experiment representative of two independent transfections. *P≤
.01 compared to control (Mann-Whitney test). (E) Increased migration and reduced tubulin acetylation in 1A9 cells stably transfected to
overexpress SIRT2 (1A9-S2) or catalytically inactive mutated SIRT2 (1A9-mutS2). Cell migration is expressed as percentage of control,
1A9-mutS2 cells (mean and SE of values from three experiments). *P < .01 compared to 1A9-mutS2 cells (Mann-Whitney test).
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invasion, and metastasis. In this study, we have demonstrated that
the modulation of SIRT2 tubulin deacetylase activity affects cell
response to the anti-motility activity of taxanes.
Paclitaxel increases the level of acetylated tubulin in endothelial and
tumor cells. Although other studies reported similar findings, this was
usually observed at high concentrations and/or long exposure times,
often associated to a cytotoxic affect [33]. We provide three lines of
evidence indicating that the effect of paclitaxel on tubulin acetylation
is associated with inhibition of cell motility rather than proliferation.
First, increase in tubulin acetylation is observed in endothelial cells
treated with 10 to 30 nM paclitaxel for 4 hours, conditions associ-
ated with inhibition of cell motility but not of proliferation. Second,
the same inverse association between tubulin acetylation and cell
motility is also observed with the taxane IDN5390 that has the same
Table 1. Activity of Taxanes on 1A9 Cells Overexpressing Wild-type or Control, Mutated SIRT2.
Paclitaxel IDN5390
Motility Prol (72 hours) Prol (4 hours) Motility Prol (72 hours) Prol (4 hours)
1A9-S2 244.3 ± 141.1 4.6 ± 2.5 22.4 ± 14.5 143.5 ± 53.3 33.1 ± 15.3 241.9 ± 128.6
1A9-mutS2 24.5 ± 4.9 4.6 ± 2.1 34.4 ± 21.8 18.8 ± 5.9 41.9 ± 25.0 442.3 ± 49.1
Data are the IC50 values (in nM) and mean and SE of values from three experiments. Proliferation (prol) was assessed by exposing cells to the compounds for 4 hours (as in the motility assay) or 72 hours.
Figure 3. Effect of SIRT2 overexpression on cell sensitivity to taxanes. Inhibition of cell motility (A, B) and induction of tubulin acetylation
(C, D) by paclitaxel (A, C) or IDN5390 (B, D) in cells overexpressing SIRT2 (1A9-S2, white symbols) or control, inactive SIRT2 (1A9-mutS2,
black symbols). Cell migration is expressed as the percentage of control, untreated cells. (E) No effect of paclitaxel on the colocalization of
SIRT2 with microtubules. HUVECs were treated with paclitaxel (100 nM) for 4 hours, fixed, and processed for double immunofluorescence
with FITC-conjugated anti–β-tubulin and anti-human SIRT2 followed by TRITC-conjugated secondary antibody. Slides were analyzed with a
confocal microscope (scale bar, 10 μm).
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anti-motility activity as paclitaxel but substantially lower cytotoxic-
ity. Third, induction of tubulin acetylation by both paclitaxel and
IDN5390 parallels inhibition of cell motility in a tumor model of
tubulin-mutated cells resistant to the antiproliferative activity of pacli-
taxel. Altogether these findings indicate that tubulin acetylation
induced by a brief exposure to taxanes reflects their anti-motility activ-
ity independently from their cytotoxic activity. Preliminary findings
indicate that tubulin acetylation was increased also by the tubulin
destabilizer combretastatin (not shown), suggesting that induction of
tubulin acetylation might be a feature common to different tubulin-
targeting inhibitors of cell motility.
This finding prompted us to investigate whether modulation of
tubulin acetylation might affect cell response to the anti-motility
activity of taxanes, focusing in particular on the two identified tubulin
deacetylases HDAC6 and SIRT2. Our data indicate that SIRT2 also
plays an important role in cell motility, as specifically demonstrated
by the findings that overexpression of SIRT2 decreased cell motil-
ity, whereas down-regulation of SIRT2 (through siRNA) increased
cell motility. This differs from the finding of Pandithage et al., who
reported an anti-motility activity of SIRT2 in a scratch assay, because of
a de-adhesive activity of SIRT2 that caused cell detachment [34]. The
experimental conditions used in the present study (three-dimensional
migration in the Boyden chamber) are quite different and less de-
pendent on cell adhesion and crawling on the substrate. Moreover,
because SIRT2 modifications, such as phosphorylation, are involved
in regulating SIRT2 ability to control tubulin acetylation and motility
and are regulated in a cell cycle manner, it might be hypothesized that
the mechanism and outcome of SIRT2 control on motility could vary
depending on stage of the cell cycle, hence justifying different results
obtained in different experimental conditions.
The molecular basis for the activity of HDAC6 and SIRT2 in cell
motility and in modulating the response to taxanes still needs to be
Figure 4. Combination of paclitaxel with tubulin deacetylase in-
hibitors. (A) Migration (diamonds) and proliferation (squares) of
endothelial cells exposed for 4 hours to paclitaxel alone (white
symbols) or in combinationwith 1.2mMsplitomicin (black symbols).
In these experiments, splitomicin alone caused 32% inhibition of
motility and 12% inhibition of proliferation. (B) Effect of a triple com-
bination of paclitaxel (PTX, 10 nM), splitomicin (Spl, 1.2 mM),
and TSA (1 μM) on endothelial cell motility, tubulin acetylation, and
proliferation. Motility and proliferation are expressed as percentage
of control activity (untreated cells). Tubulin acetylation is expressed
as fold increase of untreated cells and was calculated as the ratio of
optical density values of acetylated tubulin versus total tubulin. P <
.05 compared to control (*), control and paclitaxel alone (°), and con-
trol and each inhibitor alone (**; analysis of variance followed by
Bonferroni test).
Figure 5. Confocal microscopy analysis of the effect of paclitaxel
and tubulin deacetylase inhibitors on the localization of FOXO3a
in endothelial cells. HUVECs were exposed to paclitaxel (PTX,
10 nM), splitomicin (Spl, 1.2 mM), and TSA (1 μM) for 4 hours, pro-
cessed, and immunostained for FOXO3a as detailed in Materials
and Methods. Scale bar, 10 μm.
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clarified. The straight causal association between tubulin acetylation
and motility, initially hypothesized, was apparently confuted by the
finding that modulation of HDAC6 activity by TSA or siRNA strongly
affected tubulin acetylation but modestly modulated cell motility,
whereas the opposite was observed with modulation of SIRT2. The
apparent different potency of HDAC6 on tubulin acetylation and cell
motility might depend on additional effects of HDAC6 in this cell
type. It should also be considered that, although tubulin acetylation
is commonly detected using the 6-11B-1 antibody that recognize
acetylated Lys40, additional acetylation sites on tubulin are present
[14], which could be differentially regulated by HDAC6 and SIRT2
and modulate motility in these cells.
Both taxanes and inhibitors of histone deacetylases have been
reported to affect microtubule dynamic instability. In tumor cells,
paclitaxel suppresses microtubule dynamics (reviewed in [3]), although
in endothelial cells it surprisingly enhances dynamics at low concen-
trations compatible with inhibition of cell motility [35]. HDAC6 in
melanoma cells regulates microtubule dynamic instability, possibly
through the recruitment of kinesin-1 on microtubule and activation
of c-Jun N-terminal kinase in the microtubule environment [36]. It
has been proposed that enhancement of cell adhesion and inhibition
of motility by the histone deacetylase inhibitors TSA and tubacin is
because of a decrease in microtubule dynamics that impairs the cells’
ability to mediate the focal adhesion dynamics required for cell migra-
tion [26]. Therefore, changes in microtubule dynamics might play a
relevant role to the inhibition of motility by taxanes and inhibitors of
tubulin deacetylases.
The acetylation status of tubulin and tubulin deacetylases might
affect several molecular pathways involved in the regulation of cell
motility, including microtubule-associated protein (MAP) tau [37],
p58 [24], p53, heat shock protein 90 (Hsp90), HOXA10 [38], p53
[39], and the nuclear factor-kappaB (NF-κB) family of transcription
factor p65 [40] and cortactin [41]. Some of these molecules, such as
NF-κB [42] and Hsp90 [43], are also targeted by taxanes and therefore
represent possible convergence points between the pathways affected
by the two classes of compounds. Another possible candidate target
is FOXO3a, a member of the family of the forkhead transcription fac-
tor FOXO, that negatively regulate cell motility [44,45]. We found
that paclitaxel and splitomicin, alone and in combination, caused
FOXO3a translocation to the nucleus, a requirement for its transcrip-
tional activity. This finding is in agreement with studies showing that
paclitaxel causes the translocation of FOXO3a to the nucleus of tumor
cells [46]. By deacetylating FOXOs, SIRT1 and SIRT2 repress their
transcriptional activity [47,48], preventing their inhibitory activity
and stimulating cell motility and angiogenesis. In line with these evi-
dences, our findings indicate that SIRT inhibitors might cooperate
with paclitaxel to derepress FOXO3a, restoring its anti-motility activity.
Inhibitors of histone deacetylases are being developed as a new class
of antineoplastic agents. Although the exact mechanism of their activ-
ity is still unclear, their biologic activities possibly depend on their
antiangiogenic effect [47,49,50]. Our finding that SIRT2 regulates
endothelial cell motility points to its potential as a new target for anti-
angiogenic therapies.
The therapeutic use of histone deacetylase inhibitors has been pro-
posed in combination with chemotherapeutic agents, including taxanes
[51,52]. Our findings provide a rationale for the use of SIRT2-targeting
compounds in new approaches of combination therapies, particularly
with taxanes. Our results are in agreement with the described activity
of cambinol, an inhibitor of SIRT1 and SIRT2, that enhances the effect
of TSA on tubulin acetylation and potentiates the cytotoxicity of PTX
on lung cancer [53]. In addition, the farnesyl transferase inhibitor
Lonafarnib increases tubulin acetylation and synergizes with paclitaxel,
through a mechanism requiring a functional tubulin deacetylase [33],
further supporting the connection between modulation of tubulin
acetylation and response to taxanes.
In conclusion, this study has demonstrated that inhibition of
tubulin deacetylases enhances sensitivity to the anti-motility activity
of paclitaxel. Preclinical and clinical findings have already demonstrated
that inhibitors of histone deacetylases represent a suitable addition to
taxane-based therapies. This study points to the prospect of develop-
ing inhibitors of sirtuins as new agents for combination therapies with
taxanes to treat motility-driven diseases.
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Supplementary Materials and Methods
Mitotic Index Analysis
Exponentially growing HUVECs were exposed to paclitaxel or
IDN5390 for 4 or 24 hours. Cells were then washed with PBS, fixed
with cold methanol (20 minutes on ice), and stained with DAPI. At
least 400 nuclei per experimental condition were analyzed by a fluo-
rescence microscope (OLYMPUS IX70).
Western Blot Analysis of SIRT2 Expression in Transfected Cells
Lysates of parental and transfected 1A9 cells were electrophoresed
on a 10% SDS-PAGE gel and transferred to a nitrocellulose mem-
brane (Schleicher & Schuell). After blocking overnight at 4°C with
ECL advance blocking agent, membranes were probed with anti-
SIRT2 antibody (1:2000) for 1 hour at room temperature, followed
by peroxidase-conjugated anti-chicken IgG (Sigma) and Amersham
ECL Plus Western Blotting Detection Reagent (GE Healthcare).
In Vitro Tubulin Deacetylation Assay
Purified recombinant SIRT2-FLAG (0.284 μg) was incubated
with tubulin (10 μg; Pure, Cytoskeleton, Denver, CO) with or with-
out IDN5390 or paclitaxel (10–1000 nM) for 2 hours at room tem-
perature, after addition of NAD (1 mM, except in the negative
control), essentially as described [1]. Reaction was stopped by adding
SDS-PAGE buffer. Samples were analyzed by Western blot with
antibodies against acetylated tubulin or total tubulin. Data are
expressed as the ratio between optical density values of acetylated
tubulin and total tubulin.
Combination Index
CI was calculated as described [2] to determine whether the drugs
interacted synergistically, additively, or antagonistically. For each
combination of drug concentrations (Dsplitomicin X, Dpaclitaxel
X), producing in combination the effect X, CI was calculated as fol-
lows: CI = Dsplitomicin X/ICX, splitomicin + Dpaclitaxel X/ICX,
paclitaxel, where ICX, splitomicin and ICX, paclitaxel are the con-
centrations of each individual drug that would produce the effect X
if given alone. A confidence band was calculated around each mean
using a t distribution at the 90% probability level. Additivity was
claimed when the value CI = 1 was inside the confidence band (with
the band included in the 0.8–1.2 interval), synergism when the CI
with its confidence band was <1, and antagonism when the CI with
its confidence band was >1.
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IDN5390 43.7 ± 9.5 8341.7 ± 887.8 32.1 ± 7.5
Paclitaxel 29.0 ± 12.5 217.4 ± 117.4 1.8 ± 0.6
The table summarized previous findings on the comparison of the activity of paclitaxel and
IDN5390 [3]. Cells were exposed to the compounds for 4 hours. Data are IC50 values (in nM)
and mean and SE of values from at least three experiments.
Figure W1. Motility and mitotic index of HUVECs exposed to pacli-
taxel for 4 or 24 hours. Motility is expressed as percentage of control
motility. Mitotic index is the percentage of mitotic (or abnormal)
nuclei compared to total. Irrespective of the time of exposure, cell
motility was inhibited by concentrations of paclitaxel that did not
relevantly increase mitotic index.
Table W2. Motility and Proliferative Response of Parental 1A9 and Paclitaxel-resistant 1A9










1A9 40 ± 32 79 ± 55 69 ± 51 1905 ± 975
1A9 PTX22 30 ± 23 2650 ± 1050 47 ± 33 10207 ± 169
The table summarized previous findings on the activity of taxanes on responsive (1A9) and resistant
(1A9 PTX22) cells [3,4]. Cells were exposed to the compounds for 4 hours. Data are IC50 values
(in nM) and mean and SE of values from at least three experiments.
Figure W2. Inductionof tubulin acetylationbypaclitaxel and IDN5390
in paclitaxel-sensitive 1A9 and paclitaxel-resistant 1A9 PTX22 cells.
Data are the densitometric analysis of Western blot of Figure 1D
(representative of four different experiments). Tubulin acetylation is
expressed as fold increase of untreated cells and was calculated as
the ratio of optical density values of acetylated tubulin versus total
tubulin. In 1A9 cells, induction of tubulin acetylation by paclitaxel
increased up to 10 nM and tended to decrease at higher concen-
trations. This behavior might reflect a peculiar activity of paclitaxel
on these cells, because this was not observed when 1A9 cells
were treated with IDN5390 (Figure 1D) nor when other cell types
(HUVECs) were exposed to paclitaxel (Figure 1B). The baseline level
of tubulin acetylation in 1A9 PTX22 cells is slightly higher than in 1A9
cells. For this reason, increment in tubulin acetylation—expressed
as fold increase of untreated cells—is lower than that of 1A9 cells,
although the overall level of taxane-induced acetylation is actually
comparable or higher. Interestingly, the level of basal tubulin acetyla-
tion in 1A9 PTX22 cells is paralleled by a slightly lower ability to
migrate in theBoyden chamber assay, compared to 1A9 cells, further
supporting the correlation between tubulin acetylation and motility.
Figure W3. Western blot analysis of SIRT2 expression in parental
1A9 cells and cells stably transfected to overexpress wild-type
(1A9-S2) or catalytically inactiveGFP-SIRT2 (1A9-mutS2). (Upperpanel)
Anti-SIRT2 antibody detected a band of approximately 75 kDa,
corresponding to GFP-SIRT2. This band was similarly detectable
in the transfected cells, whereas endogenous SIRT2 (43 kDa) was
essentially undetectable in parental cells. (Lower panel) Amido black
staining of the nitrocellulose membrane to show comparable loading
and transfer.
Figure W4. Immunofluorescence analysis of themicrotubule cytoskeleton in parental 1A9 cells or cells transfected to overexpress wild-type
(1A9-S2) or catalytically inactive SIRT2 (1A9-mutS2). Transfected SIRT2 proteins are fused to GFP (GFP-SIRT2). Cells where stained with anti-
total tubulin antibody (T9026, Sigma). No relevant differences in cell morphology of cytoskeleton organization were observed in transfected
cells. Scale bar, 10 μm.
Figure W5. Confocal microscopy analysis showing that the colocalization of SIRT2 with microtubules was not affected by taxanes.
HUVECs were treated with IDN5390 or paclitaxel (100 nM) for 4 hours, fixed, and processed for double immunofluorescence with
FITC-conjugated anti–β-tubulin and anti-human SIRT2 followed by TRITC-conjugated secondary antibody. Scale bar, 10 μm.
Figure W6. Paclitaxel and IDN5390 do not inhibit SIRT2 activity. The
tubulin deacetylase activity of SIRT2 was evaluated in vitro, in the
presence of different concentrations of paclitaxel or IDN5390.
Control−, samples containing SIRT2 but not NAD were used as
a negative control (no SIRT2 activity, high acetylation). Data are
expressed as the ratio between optical density values of acetylated
tubulin and total tubulin.
Table W3. Effect of the Combination of Paclitaxel and Splitomicin on Endothelial CellMigration: CI.
Paclitaxel (nM) Splitomicin (mM) CI (Mean and SE)
1.04 0.03 >3
5.27 0.14 0.82 ± 0.45
11.85 0.32 2.43 ± 0.93
26.67 0.71 0.60 ± 0.01
40.00 1.07 0.69 ± 0.09
60.00 1.60 0.50 ± 0.10
90.00 2.40 0.36 ± 0.18
HUVEC motility was tested in the presence of the indicated concentrations of paclitaxel and splito-
micin, alone or in combination. Data were analyzed as described [2]. Additivity was claimed when
the value of CI = 1 (with confidence band included in the 0.8–1.2 interval), synergism when CI < 1,
and antagonism when CI > 1.
